<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010579</url>
  </required_header>
  <id_info>
    <org_study_id>PKU-2016KT64</org_study_id>
    <nct_id>NCT03010579</nct_id>
  </id_info>
  <brief_title>Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an randomized trial to evaluate the potential benefit of erythropoietin in the
      treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma patients with anemia on day +15 post-transplant will be randomized to erythropoietin
      group or control group. Potential benefit of erythropoietin will be evaluatedon day +60
      post-transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete hemoglobin response rate</measure>
    <time_frame>from day +15 to day +60 after autologous hematopoietic stem cell transplantation</time_frame>
    <description>proportion of complete correctors (reaching hemoglobin 120 g/L in male patients, 110 g/L in female patients) before day +60 post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of participants with red blood cell transfusions</measure>
    <time_frame>from day +15 to day +60 after autologous hematopoietic stem cell transplantation</time_frame>
    <description>proportion of participants with red blood cell transfusions from day +15 to day +60 post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants with deep vein thrombosis</measure>
    <time_frame>from day +15 to day +60 after autologous hematopoietic stem cell transplantation</time_frame>
    <description>proportion of participants with deep vein thrombosis from day +15 to day +60 post-transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anemia</condition>
  <condition>Lymphoma</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>erythropoietin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iron supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If necessaryï¼Œoral ferrous succinate, vitamins B12 and folic acid will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.</description>
    <arm_group_label>erythropoietin group</arm_group_label>
    <other_name>Erythropoiesis-Stimulating Agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron supplementation</intervention_name>
    <description>If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.</description>
    <arm_group_label>iron supplementation</arm_group_label>
    <other_name>ferrous succinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed lymphoma

          -  first autologous hematopoietic stem cell transplantation

          -  hemoglobin level less than 100 g/L on day +15 post-transplant

          -  written informed consent given by patient or his/her guardian if of minor age.

        Exclusion Criteria:

          -  HIV positive

          -  Known allergy to recombinant human erythropoietin

          -  Uncontrolled infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Cancer Hospital &amp; Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Ping Liu</last_name>
      <email>dreaming2217@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiao Pei Wang</last_name>
      <email>cadillac570@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Chairman of Lymphoma Department</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Hematinics</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

